Sunday, November 28

▷ Akeso Biomedical receives EU approval for CI-FER® as a feed additive for piglets


01.11.2021 – 07:01

Akeso Biomedical, Inc.

Burlington, Massachusetts (ots/PRNewswire)

CI-FER® reduces pathogenic biofilms, which leads to improved zootechnical performance

Akeso Biomedical, Inc. announced today that it has received approval in the European Union to market CI-FER® as a zootechnical feed additive for piglets and smaller pigs. Akeso Biomedical is a privately held company developing novel, non-antibiotic feed additive technologies to improve gut health and animal performance.

CI-FER® [Eisen(III)-citratchelat] for piglets is Akeso’s first product for the EU market based on its Fe3C technology. The company conducted five efficacy studies in the EU to show that piglets given CI-FER® grew faster, had a higher body weight and had better feed conversion rates than control piglets. The better performance was also found when comparing CI-FER® with other iron sources.

The European Food Safety Authority (EFSA) came to the conclusion that the effects of CI-FER® cannot be attributed to a nutritional-physiological effect alone, since CI-FER® performed better than other iron sources when the piglet feed was supplemented with the same iron concentrations . Three studies showed better faeces quality in weaners that received CI-FER®. In one study, parameters of oxidative stress and gene expression in the middle and ascending colon of weaned piglets were measured and showed significant improvements, suggesting health benefits after weaning.

Fe3C technology was developed at the University of Nottingham by Dr. Mahdavi, Professor Soultanas and Professor Ala’Aldeen discovered. This technology, which aims to reduce the formation of pathogenic biofilms on the surfaces of the intestinal mucosa, is protected by a portfolio of 15 issued patents. A number of infection tests carried out with CI-FER® on broilers have shown a significant reduction in intestinal bacteria, in particular, associated with animal and human diseases Campylobacter, Salmonella, Clostridium and E. coli, as well as improved zootechnical performance and lower mortality.

Simon Williams, CEO of Akeso Biomedical, said: “We are very excited to bring CI-FER® to the European market ahead of the EU ban on the medical use of zinc oxide, which is often used in high doses in veterinary medicine to improve intestinal health , used to reduce diarrhea and improve performance. “

Information about Akeso Biomedical, Inc. Akeso Biomedical, Inc. is an animal health and food safety company developing new solutions to improve animal welfare and performance and prevent foodborne diseases. For more information, send inquiries to: [email protected]

Original content by: Akeso Biomedical, Inc., transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published. Required fields are marked *